Logo image of BIAF

BIOAFFINITY TECHNOLOGIES INC (BIAF) Stock Fundamental Analysis

NASDAQ:BIAF - Nasdaq - US09076W1099 - Common Stock - Currency: USD

0.83  +0.02 (+2.47%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to BIAF. BIAF was compared to 572 industry peers in the Biotechnology industry. BIAF has a bad profitability rating. Also its financial health evaluation is rather negative. BIAF is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BIAF had negative earnings in the past year.
BIAF had a negative operating cash flow in the past year.
BIAF Yearly Net Income VS EBIT VS OCF VS FCFBIAF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -2M -4M -6M -8M

1.2 Ratios

BIAF has a worse Return On Assets (-128.91%) than 81.88% of its industry peers.
The Return On Equity of BIAF (-270.62%) is worse than 72.82% of its industry peers.
Industry RankSector Rank
ROA -128.91%
ROE -270.62%
ROIC N/A
ROA(3y)-200%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BIAF Yearly ROA, ROE, ROICBIAF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 -1K -2K -3K -4K

1.3 Margins

Looking at the Gross Margin, with a value of 35.03%, BIAF is in the better half of the industry, outperforming 75.49% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for BIAF so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 35.03%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BIAF Yearly Profit, Operating, Gross MarginsBIAF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

1

2. Health

2.1 Basic Checks

BIAF does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BIAF has more shares outstanding
The debt/assets ratio for BIAF is higher compared to a year ago.
BIAF Yearly Shares OutstandingBIAF Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2M 4M 6M 8M
BIAF Yearly Total Debt VS Total AssetsBIAF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -11.39, we must say that BIAF is in the distress zone and has some risk of bankruptcy.
BIAF's Altman-Z score of -11.39 is on the low side compared to the rest of the industry. BIAF is outperformed by 76.91% of its industry peers.
A Debt/Equity ratio of 0.18 indicates that BIAF is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.18, BIAF is not doing good in the industry: 70.52% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Altman-Z -11.39
ROIC/WACCN/A
WACC9.36%
BIAF Yearly LT Debt VS Equity VS FCFBIAF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 5M -5M 10M -10M

2.3 Liquidity

BIAF has a Current Ratio of 1.02. This is a normal value and indicates that BIAF is financially healthy and should not expect problems in meeting its short term obligations.
BIAF has a worse Current ratio (1.02) than 88.45% of its industry peers.
A Quick Ratio of 1.01 indicates that BIAF should not have too much problems paying its short term obligations.
BIAF has a worse Quick ratio (1.01) than 87.39% of its industry peers.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 1.01
BIAF Yearly Current Assets VS Current LiabilitesBIAF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

4

3. Growth

3.1 Past

BIAF shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.91%, which is quite impressive.
Looking at the last year, BIAF shows a very strong growth in Revenue. The Revenue has grown by 2827.43%.
EPS 1Y (TTM)20.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.9%
Revenue 1Y (TTM)2827.43%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%683.33%

3.2 Future

BIAF is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.25% yearly.
The Revenue is expected to grow by 77.09% on average over the next years. This is a very strong growth
EPS Next Y2.38%
EPS Next 2Y10.19%
EPS Next 3Y13.25%
EPS Next 5YN/A
Revenue Next Year285.51%
Revenue Next 2Y115.12%
Revenue Next 3Y77.09%
Revenue Next 5YN/A

3.3 Evolution

BIAF Yearly Revenue VS EstimatesBIAF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 5M 10M
BIAF Yearly EPS VS EstimatesBIAF Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BIAF. In the last year negative earnings were reported.
Also next year BIAF is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIAF Price Earnings VS Forward Price EarningsBIAF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIAF Per share dataBIAF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

A more expensive valuation may be justified as BIAF's earnings are expected to grow with 13.25% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.19%
EPS Next 3Y13.25%

More info and screens

0

5. Dividend

5.1 Amount

BIAF does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOAFFINITY TECHNOLOGIES INC

NASDAQ:BIAF (2/21/2025, 8:03:24 PM)

0.83

+0.02 (+2.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)N/A N/A
Inst Owners3.37%
Inst Owner Change14.5%
Ins Owners15.17%
Ins Owner Change6.68%
Market Cap12.93M
Analysts82.86
Price Target6.12 (637.35%)
Short Float %3.61%
Short Ratio2.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.07%
Min EPS beat(2)-9.57%
Max EPS beat(2)-4.58%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-6.68%
Min Revenue beat(2)-9.27%
Max Revenue beat(2)-4.09%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-0.61%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.38
P/FCF N/A
P/OCF N/A
P/B 4.14
P/tB 13.95
EV/EBITDA N/A
EPS(TTM)-0.8
EYN/A
EPS(NY)-0.67
Fwd EYN/A
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.46
OCFYN/A
SpS0.6
BVpS0.2
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -128.91%
ROE -270.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 35.03%
FCFM N/A
ROA(3y)-200%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover1.43
Health
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.3%
Cap/Sales 0.66%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.02
Quick Ratio 1.01
Altman-Z -11.39
F-Score3
WACC9.36%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.9%
EPS Next Y2.38%
EPS Next 2Y10.19%
EPS Next 3Y13.25%
EPS Next 5YN/A
Revenue 1Y (TTM)2827.43%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%683.33%
Revenue Next Year285.51%
Revenue Next 2Y115.12%
Revenue Next 3Y77.09%
Revenue Next 5YN/A
EBIT growth 1Y-15.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-41.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.35%
OCF growth 3YN/A
OCF growth 5YN/A